Literature DB >> 931994

Characterization of Enzyme-like activity of human hemoglobin. Properties of the hemoglobin-P-450 reductase-coupled aniline hydroxylase system.

J J Mieyal, R S Ackerman, J L Blumer, L S Freeman.   

Abstract

Human hemoglobin was characterized as an enzyme in a reconstituted aniline hydroxylase system containing hemoglobin, NADPH, rat liver cytochrome P-450 reductase, aniline and atmospheric O2. This system catalyzed p-aminophenol formation (turnover number 0.2 mol/min/mol of hemoglobin) with an efficiency similar to that which has been reported for either microsomal cytochrome P-450 or cytochrome P-450 solubilized from rat liver. The rate of the reaction was linearly dependent on hemoglobin concentration up to approximately 1 nmol of hemoglobin/ml. This linear range of hemoenzyme concentration is also similar to cytochrome P-450-catalyzed reactions. Unlike the cytochrome P-450 system, the hemoglobin system did not require a lipid cofactor for maximal activity, and much less reductase was needed for maximal activity. Aniline displayed typical Michaelis-Menten saturation kinetics as substrate, and its Km (8 mM) was the same in the absence of presence of the reductase. Catalase essentially completely inhibited p-aminophenol formation in the absence or presence of reductase. In contrast, superoxide dismutase inhibited the reductase-mediated reaction only to a small extent (if at all). No detectable hydrogen peroxide accumulated during the course of the reaction in the absence of catalase. These findings suggested a hypothetical mechanism for hemoglobin-catalyzed hydroxylation of aniline involving a hemoglobin-bound form of hydrogen peroxide (aniline-Hb3+-OOH-) as an intermediate preceding the rate-determining formation of products.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 931994

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  12 in total

1.  Aniline hydroxylation in the human red cells.

Authors:  A Tomoda; T Yubisui; M Ida; N Kawachi; Y Yoneyama
Journal:  Experientia       Date:  1977-10-15

Review 2.  Molecular controls of the oxygenation and redox reactions of hemoglobin.

Authors:  Celia Bonaventura; Robert Henkens; Abdu I Alayash; Sambuddha Banerjee; Alvin L Crumbliss
Journal:  Antioxid Redox Signal       Date:  2013-01-21       Impact factor: 8.401

3.  Ferrodoxin reductase catalyzes styrene oxidation to styrene oxide.

Authors:  G Belvedere; D Blezza; L Cantoni
Journal:  Experientia       Date:  1982-03-15

4.  Purification of 20 alpha-hydroxysteroid dehydrogenase from human erythrocytes.

Authors:  E Shirasawa; M Takeshita; Y Yoneyama
Journal:  Experientia       Date:  1980-10-15

5.  Detection of radical species in haematin-catalysed retinoic acid 5,6-epoxidation by using h.p.l.c.-e.p.r. spectrometry.

Authors:  H Iwahashi; A Ikeda; Y Negoro; R Kido
Journal:  Biochem J       Date:  1986-06-01       Impact factor: 3.857

6.  Styrene oxidation to styrene oxide in human erythrocytes is catalyzed by oxyhemoglobin.

Authors:  F Tursi; M Samaia; M Salmona; G Belvedere
Journal:  Experientia       Date:  1983-06-15

7.  Cysteine conjugate beta-lyase activity of rat erythrocytes and formation of beta-lyase-derived globin monoadducts and cross-links after in vitro exposure of erythrocytes to S-(1,2-dichlorovinyl)-L-cysteine.

Authors:  Nella Barshteyn; Adnan A Elfarra
Journal:  Chem Res Toxicol       Date:  2009-07       Impact factor: 3.739

8.  Studies on the substrate specificity and inducibility of cytochrome P-450meg.

Authors:  A Berg; J J Rafter
Journal:  Biochem J       Date:  1981-06-15       Impact factor: 3.857

9.  Incorporation of haemoglobin haem into the rat hepatic haemoproteins tryptophan pyrrolase and cytochrome P-450.

Authors:  J F Wyman; J L Gollan; W Settle; G C Farrell; M A Correia
Journal:  Biochem J       Date:  1986-09-15       Impact factor: 3.857

10.  Haemoglobin-catalysed retinoic acid 5,6-epoxidation.

Authors:  H Iwahashi; A Ikeda; R Kido
Journal:  Biochem J       Date:  1985-12-01       Impact factor: 3.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.